对外担保管理办法 贵州信邦制药股份有限公司 对外担保管理办法 第一章 总则 第一条 为规范贵州信邦制药股份有限公司（以下简称"公司"） 的对外担保行为，确保投资者的合法权益和公司财产安全，根据《中 华人民共和国民法典》、《中华人民共和国公司法》、《中华人民共 和国证券法》、《深圳证券交易所股票上市规则》、《上市公司监管 指引第8号——上市公司资金往来、对外担保的监管要求》、《深圳 证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》 等法律、法规、规范性文件以及《公司章程》等规定，制定本办法。 第二条 本办法所称对外担保是指公司以第三人身份以自有资 产或信誉为他人提供的保证、资产抵押、质押以及其他担保事宜，包 括公司为控股子公司提供的担保。 第三条 公司股东会和董事会是对外担保的决策机构，公司一切 对外担保行为，须按程序经公司股东会或董事会审议通过。未经公司 股东会或董事会的批准，公司不得对外提供担保。 第四条 公司控股子公司为公司合并报表范围内的法人或者其 他组织提供担保的，公司应当在控股子公司履行审议程序后及时披露。 按照本办法第十条，需要提交公司股东会审议的担保事项除外。 公司控股子公司为合并 ...

Core Viewpoint - Guizhou Xibang Pharmaceutical Co., Ltd. has proposed a profit distribution plan for the first half of 2025, which will be submitted for approval at the company's first extraordinary general meeting of shareholders in 2025 [1][2]. Group 1: Approval Process - The board of directors approved the profit distribution plan with 8 votes in favor, 0 against, and 0 abstentions during the eighth meeting of the ninth board on August 28, 2025 [1]. - The supervisory board also approved the profit distribution plan with 3 votes in favor, 0 against, and 0 abstentions, confirming its compliance with relevant regulations and its benefit to the company's normal operations and healthy development [1][2]. Group 2: Profit Distribution Plan Details - The company achieved a net profit of approximately 142.45 million yuan for the year, with a net profit attributable to shareholders of approximately 107.20 million yuan [2]. - The profit distribution plan proposes a cash dividend of 0.30 yuan per 10 shares (including tax), with a total expected cash dividend of approximately 56.89 million yuan [2]. - The total share capital after the repurchase of 47,445,540 shares is 1,896,406,328 shares, which serves as the basis for the distribution [2]. Group 3: Legality of Cash Dividend Plan - The cash dividend plan is deemed legal, compliant, and reasonable, adhering to the Company Law, Securities Law, and relevant guidelines [3]. - The plan is designed to ensure the company's normal operations and long-term development while providing continuous returns to investors [2][3].

Meeting Overview - The ninth board meeting of Guizhou Xibang Pharmaceutical Co., Ltd. was held on August 28, 2025, in a combined onsite and remote format, with all 8 directors present [1] - The meeting was legally convened and conducted in accordance with relevant laws and regulations [1] Resolutions Passed - The board unanimously approved the profit distribution plan for the first half of 2025, considering the company's profitability and overall financial status [2] - The proposal to amend relevant provisions of the company's articles of association was also approved [2][3] - The company plans to abolish the supervisory board, transferring its responsibilities to the audit committee of the board, pending approval from the shareholders' meeting [3] - Several governance system revisions were approved to enhance operational standards and governance effectiveness [4] Future Actions - All resolutions, including the profit distribution plan and governance amendments, are subject to approval at the company's first extraordinary general meeting of 2025 [2][3][4] - The company has announced the convening of the first extraordinary general meeting of 2025 [4][6]

Meeting Details - The ninth supervisory board's eighth meeting of Guizhou Xinbang Pharmaceutical Co., Ltd. was held on August 28, 2025, in Guiyang, combining in-person and remote participation [1] - The meeting was legally convened with all three supervisors present, including one participating via remote communication [1] Meeting Resolutions - The supervisory board reviewed and approved the procedures for the preparation and review of the 2025 semi-annual report and its summary, confirming compliance with legal and regulatory requirements, and asserting that the report accurately reflects the company's actual situation without any false statements or omissions [1] - The board unanimously agreed (3 votes in favor, 0 against, 0 abstentions) on the 2025 semi-annual profit distribution plan, which aligns with relevant regulations and the company's profit distribution policy, ensuring no harm to shareholders, particularly minority shareholders [2] - The profit distribution plan will be submitted for approval at the company's first extraordinary general meeting of shareholders in 2025 [2]

Meeting Overview - Guizhou Xinbang Pharmaceutical Co., Ltd. convened its 9th Board of Directors' 8th meeting on August 28, 2025, where the proposal to hold the 2025 First Extraordinary General Meeting of Shareholders was approved with 8 votes in favor, 0 against, and 0 abstentions [1][2] Meeting Details - The on-site meeting is scheduled for September 17, 2025, at 14:30 [1] - Online voting will also take place on September 17, 2025, from 9:15 to 15:00 [2][3] - Shareholders must register by September 11, 2025, to participate [2] Agenda Items - The meeting will address several proposals, including: - Revision of the "Management System for Senior Management Compensation and Performance Evaluation" [3] - Revision of the "Management System for Transactions with Related Parties" [3] - Proposal 2 requires a special resolution, needing more than two-thirds approval from attending shareholders [3] - A total of 10 sub-proposals will be voted on individually [3] Registration Process - Registration for the meeting will occur on September 16, 2025, from 9:00 to 16:00 [4] - Various methods for registration are provided for different types of shareholders [4] Voting Procedures - Shareholders can vote through the Shenzhen Stock Exchange trading system and internet voting system [5][6] - Specific procedures for casting votes are outlined, including the requirement for first valid votes to be counted [5][6] Documentation - Relevant documents for the meeting include the resolutions from the 8th Board of Directors' meeting and the 8th Supervisory Board meeting [5]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 贵州信邦制药股份有限公司（以下简称"公司"）于 2025 年 8 月 28 日召开的第九届董事会第八次会议，逐项审议通过了《关于修 订、制定公司部分治理制度的议案》。根据《公司法》、《证券法》、 《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公 司募集资金监管规则》、《深圳证券交易所股票上市规则》、《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》等最新规定，为进一步提升公司规范运作水平，完善公司治理制 度，公司结合实际情况，拟对现有的部分公司治理制度进行修订，同 时制定相关制度。修订及制定的制度具体如下： | 序号 | 制度名称 | 类型 | 是否需提交股 | | --- | --- | --- | --- | | | | | 东大会审议 | | 1 | 《股东会议事规则》 | 修订 | 是 | | 2 | 《董事会议事规则》 | 修订 | 是 | | 3 | 《独立董事工作制度》 | 修订 | 是 | | 4 | 《董事、高级管理人员薪酬及绩效考核管理制 | 修订 | 是 ...

贵州信邦制药股份有限公司 2025 年半年度 财务报告 2025 年 8 月 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：贵州信邦制药股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 998,531,222.17 | 1,015,515,313.40 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | | | | 衍生金融资产 | | | | 应收票据 | 78,419,617.46 | 83,953,750.71 | | 应收账款 | 2,481,121,499.98 | 2,534,340,405.01 | | 应收款项融资 | 89,000,541.25 | 73,196,329.41 | | 预付款项 | 150,367,011.28 | 162,131,632.76 | | 应收保费 | | | | 应收分保账款 | | | | 应 ...

2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | | 往来方与上市公 | 上市公司 | 2025 年期初 | 2025 | 年半年度 | 2025 年半年度 | 2025 年半年度 | 2025 年半年度 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 其他关联资金往来 | 资金往来方名称 | | | | | 往来累计发生金额 | 往来资金的利息 | | | 往来形成原因 | 往来性质 | | | | 司的关联关系 | 核算的会计科目 | 往来资金余额 | | （不含利息） | （如有） | 偿还累计发生金额 | 期末往来资金余额 | | | | 控股股东、实际控制 | | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | | | 贵州卓大医药有限责任公司 | 控股子公司 | 其他应收款 | 12,400.00 | | | | 700.00 | 11,700.00 | 财务资助 | 非经营性往来 | | | 贵州医科 ...

贵州信邦制药股份有限公司 章程修正案 贵州信邦制药股份有限公司（以下简称"公司"）第九届董事会 第八次会议审议通过了《关于取消监事会并修订<公司章程>的议案》。 根据《公司法》、《证券法》、《深圳证券交易所股票上市规则》、《上市 公司章程指引》等有关法律法规、规范性文件等有关规定，并结合公 司实际情况，公司拟对《公司章程》进行修订，具体情况如下： 1、将《公司章程》全文"股东大会"统一修订为"股东会"； 2、删除《公司章程》"第七章 监事会"内容； 3、除上述调整外，《公司章程》其他修订内容如下： | 序号 | 修订前 | 修订后 | | --- | --- | --- | | | 因新增、删减或排列相关条款导致原序号发生变化，或仅将"股东大会"修订为"股东会"，而不涉 | | | | 及其他内容变化的，不一一列示说明。 | | | | 第一条 为维护贵州信邦制药股份有限公 | 第一条 为维护贵州信邦制药股份有限公 | | | 司（以下简称"公司"）、股东和债权人的合法 | 司（以下简称"公司"）、股东、职工和债权人 | | | 权益，规范公司的组织和行为，根据《中华人 | 的合法权益，规范公司的组织和行为， ...

证券代码：002390 证券简称：信邦制药 公告编号：2025-026 贵州信邦制药股份有限公司 关于修订《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 贵州信邦制药股份有限公司（以下简称"公司"）于 2025 年 8 月 28 日召开的第九届董事会第八次会议审议通过了《关于取消监事 会并修订<公司章程>的议案》，现将具体情况公告如下： 一、关于修订《公司章程》并取消监事会的具体情况 根据《公司法》、《深圳证券交易所股票上市规则》、《上市公 司章程指引》等相关法律、法规及规章的规定，结合公司实际情况， 公司拟对《公司章程》相关条款进行修订。章程具体修订内容详见刊 登于巨潮资讯网（http://www.cninfo.com.cn）的《公司章程》、《章 程修正案》。 同时，根据《关于新〈公司法〉配套制度规则实施相关过渡期安 排》、《上市公司章程指引》等相关规定，为进一步提升公司治理效 能，公司拟不再设置监事会及监事，由董事会审计委员会行使《公司 法》规定的监事会的职权。 《关于取消监事会并修订<公司章程>的议案》尚需提交公司2025 年第一次临 ...